We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > diabetic retinopathy

News List

REGENXBIO Doses First Patient in RGX-314 Trial for Diabetic Retinopathy americanpharmaceuticalreview
December 31, 2020
REGENXBIO announced the first patient has been dosed in ALTITUDE, a Phase II trial to evaluate the suprachoroidal delivery of RGX-314 using the SCS Microinjector for the treatment of diabetic retinopathy (DR).
Neovascularization inhibitor sales will near $7 bn in diabetic retinopathy market in 2029: GlobalData expresspharma
September 18, 2020
This increase is expected to be driven by the demonstrable efficacy of these products in reducing the rate of angiogenesis and sight loss in diseases such as DR, diabetic macular oedema and retinal vein occlusion.
Regenxbio Announces FDA Clearance of IND for Trial of Diabetic Retinopathy Treatment americanpharmaceuticalreview
August 26, 2020
Regenxbio announced the clearance of the Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to evaluate the suprachoroidal delivery of RGX-314 in patients with diabetic retinopathy (DR).
Regeneron's Eylea pads its armor with diabetic retinopathy approval fiercepharma
May 15, 2019
With a major challenger on the fast track to approval in Novartis’ brolucizumab, Regeneron’s Eylea has been on the hunt for a new indication to boost its best-in-class sales.